慢性心力衰竭患者血浆H2松弛素的表达被引量：3

Study on the expression of plasma H2 relaxin level in patients with chronic heart failure

下载PDF

导出

摘要目的：探讨内源性H2松弛素（H2RLX）在慢性心力衰竭患者中的表达以及与NYHA分级的关系，研究其对慢性心力衰竭患者预后的预测作用。方法：选取2012年7月至2012年12月住院患者140例，慢性心力衰竭组109例，对照组31例。2组患者均予入院第1天清晨平卧、静息状态下抽取静脉血以检测LDL-胆固醇、血红蛋白、空腹血糖、肌酐清除率、脑钠肽（BNP）等，用ELISA法检测血H2RLX、I型胶原的表达量，心脏超声评估左心室射血分数（LVEF）。结果：①慢性心力衰竭组血浆H2RLX水平[0.604（0.419～0.743）pg/mL]，与对照组[0.390（0.355～0.425）pg/mL]比较显著升高，差异有统计学意义（P＜0.05）；②NYHA分级越高，慢性心力衰竭组H2RLX和I型胶原升高趋势越显著，差异有统计学意义（P＜0.05）；③H2RLX与I型胶原呈显著正相关，差异有统计学意义（r=0.885，P＜0.001）；④H2RLX水平对慢性心力衰竭患者半年内心血管事件预后有预测作用。结论：慢性心力衰竭患者血浆中H2RLX表达升高，其可能参与心室纤维化过程；血浆H2RLX水平有助于慢性心力衰竭严重程度的评估，并对心血管事件的预后有预测作用。 Objective： To explore the expression of endogenous H2 relaxin hormone in chronic heart failure patients, and the relations with NYHA classiifcation, to study its effect on the prognosis of patients with chronic heart failure prediction.Methods： One hundred and forty patients were selected for reseach from July 2012 to September 2012, in the First Afifliated Hospital of Wenzhou Medical University, 109 cases for chronic heart failure group and 31 cases for control group. In the early morning of the ifrst day after admission, patients in each group were exsanguinated in supine, resting status for some venous blood to detect, LDL-cholesterol, he-moglobin, fasting blood glucose, creatinine clearance rate, brain natriuretic peptide （BNP） and so on. ELISA was performed to analyze the plasma concentration of H2RLX, collagen I. In addition, echocardiography inspection was given to estimate left ventricular ejection fraction.Results：①Plasma H2RLX level of chronic heart failure patients [0.604 （0.419-0.743）] pg/mL was signiifcantly higher than that of control group [0.390 （0.355-0.425）] pg/mL. The difference was statistically signiifcant （P〈0.05）.②The tendency as classiifcation of NYHA showed that the plasma level of H2RLX and collagen I both increased in all of heart failure （HF） patients as aggravation of cardiac dysfunction. The difference was statistically signiifcant （P〈0.05）.③Plasma level of H2RLX and type I collagen showed signiifcant correlation, there was statistically signiifcant （r=0.889,P＆lt;0.001）.④H2RLX levels in chronic heart failure patients could predict the cardiovascular event in one hundred and eighty days.Conclu-sion： The H2RLX levels elevate in patients with chronic heart failure, which may involve in ventricular ifbrosis; H2RLX may help to make preliminary estimation of the severity of chronic heart failure and H2RLX plasma lev-els may predict the prognosis of cardiovascular events.

作者朱艳艳潘嘉林陈灵芝周希郑高暑林杰黄伟剑张怀勤周浩

机构地区温州医科大学附属第一医院心血管内科温州医科大学附属第二医院心血管内科温州市中心医院检验科

出处《温州医学院学报》 CAS 2015年第1期22-25,共4页 Journal of Wenzhou Medical College

基金浙江省自然科学基金资助项目(LY12H02004)

关键词 H2松弛素慢性心力衰竭纤维化严重程度预后 H2 relaxin chronic heart failure ifbrosis severity prognosis

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献17

1Hisaw FL. Experimental relaxation of the pubic ligament of the guinea pig[J]. Exp Biol Med, 1926, 23(8): 661-663.
2Bani D, Nistri S, Formigli L, et al. Prominent role of re- laxin in improving postinfarction heart remodeling[J]. Ann NY Acad Sci, 2009, 1160(1): 269-277.
3Teerlink JR, Cotter G, Davison BA, et al. Relaxin in Acute Heart Failure (RELAX-AHF) Investigators Serelaxin, re- combinant human relaxin-2, for treatment of acute heart fail- ure (RELAX-AHF): a randomised, placebo-controlled trial [J]. Lancet, 2013, 381(9860): 29-39.
4Hocher B, Ziebig R, Krause R, et al. Relaxin is an indepen- dent risk factor predicting death in male patients with end-Stage kidney disease[J]. Circulation, 2004, 109(19): 2266-2268.
5Dschietzig T, Teichman S, Unemori E, et al. First Clinical Experience with Intravenous Recombinant Human Relaxinin Compensated Heart Failure[J]. Ann NY Acad Sci, 2009, 1160: 387-392.
6杜晓军,范粉灵,徐琦.松弛素在逆转心肌纤维化和主动脉硬化中的作用及其机制[J].中国医学前沿杂志（电子版）,2011,3(5):24-28. 被引量：5
7Debrah DO, Conrad KP, Jeyabalan A, et al. Relaxin increas- es cardiac output and reduces systemic arterial load in hypertensive rats[J]. Hypertension, 2005, 46(4): 745-750.
8Samuel CS, Cendrawan S, Gao XM, et al. Relaxin remod- els fibrotic healing following myocardial infarction[J]. Lab Invest, 2011, 91(5): 675-690.
9Hudson P, John M, Crawford R, et al. Relaxin gene expres- sion in human ovaries and the predicted structure of a hu- man preprorelaxin by analysis of eDNA clones[J]. EMBO J, 1984, 3(10):2333-2339.
10Kupari M, Mikkola TS, Turto H, et al. Is the pregnancy hor- mone relaxin an important player in human heart failure?[J]. Eur J Heart Fail, 2005, 7(2): 195-198.

二级参考文献25

1Berk BC;Fujiwara K;Lehoux S.ECM remodeling in hypertensive heart disease[J]Journal of Clinical Investigation,2007(03):568–575.
2Greenwald SE.Ageing of the conduit arteries[J]Journal of Pathology,2007(02):157-172.
3Avolio AP;Van Bortel LM;Boutouyrie P.Role of pulse pressure amplifi cation in arterial hypertension:experts' opinion and review of the data[J]Hypertension,2009(02):375-383.
4Blacher J;Safar ME.Large-artery stiffness,hypertension and cardiovascular risk in older patients[J]Cardiovascular Medicine,2005(09):450-455.
5Marque V;Grima M;Kieffer P.Withdrawal reveals lack of effect of prolonged antihypertensive treatment on intrinsic aortic wall stiffness in senescent spontaneously hypertensive rats[J]Clinical and Experimental Pharmacology and Physiology,2002(10):898-904.
6Sherwood OD.Relaxin's physiological roles and other diverse actions[J]Endocrine Reviews,2004(02):205-234.
7Bathgate RA;Ivell R;Sanborn BM.International Union of Pharmacology:Recommendations for the nomenclature of receptors for relaxin family peptides[J]Pharmacological Reviews,2006(01):7-31.
8Du XJ;Bathgate RAD;Samuel CS.Cardiovascular effects of relaxin:from basic science to clinical therapy[J]Nature Reviews Cardiology,2010(01):48-58.
9Dschietzig T;Bartsch C;Baumann G.RXFP1-inactive relaxin activates human glucocorticoid receptor:further investigations into the relaxin-GR pathway[J]Regulatory Peptides,2009(1-3):77-84.
10Conrad KR.Maternal vasodilation in pregnancy:the emerging role of relaxin[J]American Journal of Physiology-Regulatory Integrative and Comparative Physiology,2011(02):R267-R275.